Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases

IF 4.4 2区 医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2025-03-01 Epub Date: 2025-01-31 DOI:10.1016/j.lungcan.2025.108414
Zhiyuan Yao , Tong Qiu , Changlei Li , Weimao Kong , Guangqi Li , Peng Song , Guohua Wang , Wenjie Jiao
{"title":"Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases","authors":"Zhiyuan Yao ,&nbsp;Tong Qiu ,&nbsp;Changlei Li ,&nbsp;Weimao Kong ,&nbsp;Guangqi Li ,&nbsp;Peng Song ,&nbsp;Guohua Wang ,&nbsp;Wenjie Jiao","doi":"10.1016/j.lungcan.2025.108414","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations.</div></div><div><h3>Method</h3><div>Paraffin-embedded specimens of primary PACC tissues pathologically confirmed at the Affiliated Hospital of Qingdao University within the past decade were collected. We comprehensively evaluated the diversity of molecular alterations in PACC using immunohistochemistry (IHC) staining, fluorescence <em>in-situ</em> hybridization (FISH), and next-generation sequencing (NGS). Furthermore, the potential correlations between MYB rearrangement status and clinicopathological features were thoroughly analyzed.</div></div><div><h3>Result</h3><div>Twenty-one specimens of primary PACC were collected, including eighteen of the typical type and three of the solid-basaloid type. Fifteen (71.4 %) specimens exhibited positive MYB staining and MYB rearrangements. Notably, neither clinicopathological parameters nor MYB rearrangement predicted patients’ overall survival (OS). However, MYB non-rearrangement was associated with a significantly higher rate of lymph node metastasis (75 % vs. 8.3 %, P = 0.027).</div></div><div><h3>Conclusion</h3><div>Investigating the heterogeneity and multimolecular characteristics of PACC based on different pathological types emerges as a potentially innovative strategy to pinpoint suitable candidates for targeted therapies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108414"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225000352","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations.

Method

Paraffin-embedded specimens of primary PACC tissues pathologically confirmed at the Affiliated Hospital of Qingdao University within the past decade were collected. We comprehensively evaluated the diversity of molecular alterations in PACC using immunohistochemistry (IHC) staining, fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS). Furthermore, the potential correlations between MYB rearrangement status and clinicopathological features were thoroughly analyzed.

Result

Twenty-one specimens of primary PACC were collected, including eighteen of the typical type and three of the solid-basaloid type. Fifteen (71.4 %) specimens exhibited positive MYB staining and MYB rearrangements. Notably, neither clinicopathological parameters nor MYB rearrangement predicted patients’ overall survival (OS). However, MYB non-rearrangement was associated with a significantly higher rate of lymph node metastasis (75 % vs. 8.3 %, P = 0.027).

Conclusion

Investigating the heterogeneity and multimolecular characteristics of PACC based on different pathological types emerges as a potentially innovative strategy to pinpoint suitable candidates for targeted therapies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
原发性肺腺样囊性癌:21例临床病理特征及分子改变的研究
背景:原发性肺腺样囊性癌是一种罕见的恶性肿瘤。尽管ACC的研究越来越复杂,但很少有研究深入研究起源于肺部的ACC的独特分子改变及其临床特征的相关性。方法收集青岛大学附属医院近十年病理证实的原发性PACC组织石蜡包埋标本。我们使用免疫组织化学(IHC)染色、荧光原位杂交(FISH)和下一代测序(NGS)综合评估了PACC分子改变的多样性。此外,我们还深入分析了MYB重排状态与临床病理特征的潜在相关性。结果共采集原发性前列腺癌标本21份,其中典型型18份,固体玄武岩型3份。15例(71.4%)MYB染色阳性,MYB重排。值得注意的是,临床病理参数和MYB重排都不能预测患者的总生存期(OS)。然而,MYB非重排与更高的淋巴结转移率相关(75%对8.3%,P = 0.027)。结论基于不同病理类型研究PACC的异质性和多分子特征是一种潜在的创新策略,可以确定合适的靶向治疗候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
期刊最新文献
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2) First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1